Harmony Biosciences (HRMY) Tops Q1 EPS by 20c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/24/2026

1. DECK
2. RNG
3. WDC
4. BYD
5. WCN
6. SPOT
7. BMY
8. SPY
9. FIX
10. TSCO

Go back to Harmony Biosciences (HRMY) Tops Q1 EPS by 20c

Harmony Biosciences Reports First Quarter 2022 Financial Results and Business Updates

May 3, 2022 7:30 AM EDT

WAKIX® (pitolisant) Net Revenue of $85.3 Million for First Quarter 2022 Increase of 43% vs. the Same Period in 2021

WAKIX Surpasses $500 Million in Cumulative Net Revenue Since Launch

Initiated Phase 3 Clinical Trial in Patients with Idiopathic Hypersomnia

Conference Call and Webcast to be Held Today at 8:30 a.m. ET 

PLYMOUTH MEETING, Pa., May 03, 2022 (GLOBE NEWSWIRE) -- Harmony Biosciences Holdings, Inc. (Harmony or the Company) (Nasdaq: HRMY), a pharmaceutical company focused on delivering innovative therapies that improve the health of people living with... More